Angina is the cinderella to acute coronary syndromes, with uncertainty about how well and consistently patients are investigated and treated by the NHS. The new national service framework standard in England for patients with angina is investigation and treatment to relieve pain and reduce coronary risk,1 and the rapid access chest pain clinic is the preferred way of delivering such care.2,3 The goal was to have 50 such clinics by April 2001, but there are already 100, with nationwide rollout gathering pace. What is the rationale for such clinics and do they work?
Patients presenting for the first time to their general practitioner with suspected angina can now be assessed by a specialist through a rapid access chest pain clinic. Patients with suspected acute coronary disease should still be sent direct to the casualty department; if they are then diagnosed as having exertional angina they too can be referred to the rapid access clinic, rather than a traditional outpatient clinic or back to general practice. There is observational evidence that these rapid access clinics reduce admissions.4 Thus they will close the loop between community and hospital for cardiac chest pain, whatever the patient's first point of medical contact. Although general practitioners do not have to refer all patients with suspected angina for a specialist opinion, rapid access clinics will soon make this the norm.
The concept of a chest pain clinic is not new,5 and the rationale for rapid assessment of this symptom is simple. Firstly, exertional cardiac chest pain is common, frightening for the patient, and worrying for general practitioners and casualty officers since it can be difficult to distinguish cardiac from non-cardiac pain. Secondly, exertional angina can progress to unstable angina, acute myocardial infarction, or death.5,6 Predicting a stable clinical course from symptoms alone is difficult. A resting electrocardiogram is usually unhelpful in assessing risk as it is normal in over 90% of new patients.7 Life threatening complications occur in the short term, sometimes within days or weeks of medical presentation. In the only natural history study of exertional angina in the community, based in a chest pain clinic, 14% of patients receiving only sublingual glyceryl trinitrate developed serious complications within six months of presentation,5 most within the first four weeks. In a more recent community study of angina, based in a chest pain clinic, 11% died or had a myocardial infarction over 15 months despite prompt revascularisation in a fifth of all new cases.6
Thirdly, non-invasive techniques can risk stratify patients by showing the degree of reversible ischaemia,8 thus identifying those requiring immediate angiography. Fourthly, treatments to relieve symptoms and improve prognosis can be given: aspirin,9 statins,10 angiotensin converting enzyme inhibitors,11 and revascularisation12—the last can be targeted at highest risk patients only after specialist investigation. Rapid access chest pain clinics inevitably increase the number of patients assessed at hospital. In one district a clinic doubled the number of new cases of angina diagnosed by the cardiology service.3 As a result the number of patients requiring coronary angiography and revascularisation will also increase. Finally, for most patients with chest pain considered by a specialist to be non-cardiac, rapid access clinics provide swift reassurance.
Thus launching rapid access chest pain clinics nationwide has a strong clinical rationale and will radically transform assessment and management of angina. Yet what evidence is there that this model of care will improve outcomes? There is no randomised controlled trial to show that prompt assessment and management reduces coronary morbidity and mortality. A priori, a reduction in coronary risk is expected, but its size and long term impact are unknown. We need a clinical trial, but the political imperative of the national service framework makes such a trial seem unrealistic. Rapidity of assessment is also an open question—same day, within two weeks, or a more relaxed approach? Published experience of chest pain clinics is based on same day (excluding weekends) assessment.4–8 The framework standard of assessment within two weeks is arbitrary. And rapidity of assessment begs a question about rapidity of management. How rapidly can coronary angiography be performed in high risk patients? And for those requiring revascularisation how rapidly should this happen after angiography? The framework waiting time goal for surgical revascularisation is within three months of deciding to operate, but this is pragmatic rather than evidence based. A clinical trial is required to assess the impact of rapid medical and surgical management of exertional angina.
The staffing of a rapid access clinic is another open question. Various options exist—non-consultant career staff grades, trained general practitioners, or trained cardiac nurses and technicians. All depart from the principle of a specialist opinion, unless a cardiologist reviews every case. These alternative models have yet to be evaluated, and there is a pressing need to do so.
Assessment of exertional angina through rapid access clinics is a bold national initiative. Patients with angina, like those with acute coronary syndromes, will now gain prompt access to cardiology services. We need to capture this unique national experience by monitoring the frequency, management, and prognosis of exertional angina through these clinics. To do so we need to collect a common core dataset to form a national database. Evaluating different service models for rapid chest pain assessment is also required if hard pressed district cardiac services are to cope with yet more referrals. The number of patients presenting with exertional angina for the first time is about 22 600 a year in the United Kingdom.6 If specialist cardiac nurses and technicians can offer a protocol driven assessment of these patients then rapid access clinics are a more practical proposition for every hospital. Ultimately, we need to know if both rapid assessment and rapid management of angina presenting in the community will reduce coronary morbidity and mortality.
References
- 1.Department of Health. The national service framework for coronary heart disease. London: Stationery Office; 2000. [Google Scholar]
- 2.Timmis AD. Speeding up cardiac care. Impact. 1999;1:1–3. [Google Scholar]
- 3.Sutcliffe SJ, Fox KF, Wood DA. How to set up and run a rapid access chest pain clinic. Br J Cardiol. 2001;7:692–702. [Google Scholar]
- 4.Newby DE, Fox KAA, Flint LL, Boon NA. A “same-day” direct access chest pain clinic: improved management and reduced hospitalisation. Q J Med. 1998;91:333–337. doi: 10.1093/qjmed/91.5.333. [DOI] [PubMed] [Google Scholar]
- 5.Duncan B, Fulton M, Morrison SL, Lutz W, Donald KW, Kerr F, et al. Prognosis of new and worsening angina pectoris. BMJ. 1976;i:981–985. doi: 10.1136/bmj.1.6016.981. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 6.Gandhi MM. Incidence, clinical characteristics, and short-term prognosis of angina pectoris. Br Heart J. 1995;73:193–198. doi: 10.1136/hrt.73.2.193. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 7.Norrell M, Lythall D, Coghlan G, Cheng A, Kushawa S, Swan J, et al. Limited value of the resting electrocardiogram in assessing patients with recent onset chest pain: lessons from a chest pain clinic. Br Heart J. 1992;67:53–56. doi: 10.1136/hrt.67.1.53. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 8.Jain D, Fluck D, Sayer RW, Ray S, Paul EA, Timmis AD. Ability of a one-stop chest pain clinic to identify patients with high cardiac risk seen in a district general hospital. J Royal Coll Phys Lond. 1997;31:401–404. [PMC free article] [PubMed] [Google Scholar]
- 9.Antiplatelet Trialists' Collaboration. Collaborative overview of randomised trials of antiplatelet therapy I: Prevention of death, myocardial infarction, and stroke by prolonged anti-platelet therapy in various categories of patients. BMJ. 1994;308:81–106. [PMC free article] [PubMed] [Google Scholar]
- 10.Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S) Lancet. 1994;344:1383–1389. [PubMed] [Google Scholar]
- 11.Yusuf S, Sleight P, Pogue J, Bosch J, Davies R, Dagenais G. Effects of an angiotensin-converting enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation (HOPE) Study Investigators. N Engl J Med. 2000;342:145–153. doi: 10.1056/NEJM200001203420301. [DOI] [PubMed] [Google Scholar]
- 12.Yusuf S, Zucker D, Peduzzi P, Fisher LD, Takaro T, Kennedy JW, et al. Effect of coronary artery bypass graft surgery on survival: Overview of 10-year-results from randomised trials by the Coronary Artery Bypass Graft Surgery Trialists Collaboration. Lancet. 1994;344:563–570. doi: 10.1016/s0140-6736(94)91963-1. [DOI] [PubMed] [Google Scholar]